ALTERITY THERAPEUTICS-ADR (ATHE) Stock Price, Forecast & Analysis
USA - NASDAQ:ATHE - US02155X2053 - ADR
ATHE Key Statistics, Chart & Performance
The current stock price of ATHE is 3.7899 USD. In the past month the price decreased by -24.35%. In the past year, price increased by 242.98%.
ATHE Latest News, Press Relases and Analysis
ATHE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.68 | 412.01B | ||
| AMGN | AMGEN INC | 15.38 | 181.04B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.01 | 111.32B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.15 | 72.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 887.73 | 59.35B | ||
| INSM | INSMED INC | N/A | 41.09B | ||
| NTRA | NATERA INC | N/A | 28.75B | ||
| BIIB | BIOGEN INC | 9.65 | 23.67B | ||
| INCY | INCYTE CORP | 16.86 | 21.14B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.49 | 20.88B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.13 | 14.56B |
Related stock screener links
About ATHE
Company Profile
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Company Info
ALTERITY THERAPEUTICS-ADR
Level 14, 350 Collins Street
Melbourne VICTORIA VIC 3000 AU
CEO: David A. Stamler
Employees: 9
Phone: 61393494906
ALTERITY THERAPEUTICS-ADR / ATHE FAQ
What does ATHE do?
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
What is the current price of ATHE stock?
The current stock price of ATHE is 3.7899 USD. The price increased by 3.27% in the last trading session.
Does ATHE stock pay dividends?
ATHE does not pay a dividend.
How is the ChartMill rating for ALTERITY THERAPEUTICS-ADR?
ATHE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How many employees does ALTERITY THERAPEUTICS-ADR have?
ALTERITY THERAPEUTICS-ADR (ATHE) currently has 9 employees.
Can you provide the upcoming earnings date for ALTERITY THERAPEUTICS-ADR?
ALTERITY THERAPEUTICS-ADR (ATHE) will report earnings on 2026-02-26.
What is the ownership structure of ALTERITY THERAPEUTICS-ADR (ATHE)?
You can find the ownership structure of ALTERITY THERAPEUTICS-ADR (ATHE) on the Ownership tab.
ATHE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ATHE. When comparing the yearly performance of all stocks, ATHE is one of the better performing stocks in the market, outperforming 96.78% of all stocks.
ATHE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ATHE. ATHE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ATHE Financial Highlights
Over the last trailing twelve months ATHE reported a non-GAAP Earnings per Share(EPS) of -0.58. The EPS increased by 59.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.39% | ||
| ROE | -28.65% | ||
| Debt/Equity | 0 |
ATHE Forecast & Estimates
For the next year, analysts expect an EPS growth of 100% and a revenue growth 1302.63% for ATHE